Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(0.06) by 2016.67 percent. This is a 252.78 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $240.00 million which missed the analyst consensus estimate of $268.30 million by 10.55 percent. This is a 27.05 percent decrease over sales of $329.00 million the same period last year.
Emergent BioSolutions Q3 EPS $(1.27) Misses $(0.06) Estimate, Sales $240.00M Miss $268.30M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(0.06) by 2016.67 percent. This is a 252.78 percent decrease over losses of $(0.36) per
Related Posts
CATL’s 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification
XPeng Inc (NYSE: XPEV) has diversified its battery suppliers and does not count industry giant CATL as its primary supplier, said Brian Gu, President of the Chinese electric car maker, according to
GitLab’s Surprising Quarter: What Are Analysts Whispering About Its Future?
Truist Securities analyst Miller Jump maintained GitLab Inc (NASDAQ: GTLB) with a Buy and raised the
What’s Going On With Badger Meter Stock Thursday?
Badger Meter reported 23% sales growth YoY, beating consensus. EPS of $0.99 also exceeded expectations. Utility water sales increased 29%, while flow instrumentation sales declined 3%. Gross margin decreased, but operating margin improved. Stock price rose.